SaNOtize
An innovative biotech company, using a patented platform technology for topical delivery of NO, to treat upper respiratory and dermal infections.
Launch date
Employees
Market cap
-
Enterprise valuation
€87—131m (Dealroom.co estimates Aug 2022.)
Vancouver British Columbia (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Angel | ||
| N/A | $200k | Angel | |
$1.3m | Early VC | ||
$5.8m | Early VC | ||
$5.6m | Series A | ||
* | $10.0m | Early VC | |
* | $24.0m | Series B | |
| Total Funding | €42.6m | ||
Related Content
Recent News about SaNOtize
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.